BridgeBio Pharma's Acoramidis Continues To Show Disease-modifying Effects In ATTR-CM

BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company, on Monday announced new data from its Phase 3 ATTRibute-CM study of Acoramidis, demonstrating disease-modifying effects across clinical outcomes, biomarkers, and functional capacity in transthyretin amyloid cardiomyopathy.

The phase 3 ATTRibute-CM study formed the basis of FDA approval for Acoramidis.

Acoramidis, a transthyretin stabilizer, received FDA approval in November 2024 for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.